Palvella Therapeutics’ QTORIN Rapamycin 3.9% Anhydrous Gel Shows Promise for Microcystic LMs
Palvella Therapeutics, Inc.’s QTORIN rapamycin 3.9% anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. There are no U.S. Food and Drug Administration (FDA)-approved therapies for microcystic LMs. The FDA has granted Breakthrough Therapy […]